| DB ID | MyCo_3202 |
| Title | Initial serum (1,3)-β-D-glucan as a predictor of mortality in proven candidaemia: findings from a retrospective study in two teaching hospitals in Italy and Brazil |
| Year | 2015 |
| PMID | 26070961 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Predictive |
| Biomolecule | Protein |
| Geographical Location | Italy |
| Cohort | The study was conducted in two large teaching hospitals in Italy and Brazil. From January 2009 to June 2014, all patients with proven candidaemia who underwent a BDG test within 96 hours before or after the rst positive blood culture were included in the study. The primary end point was 28-day mortality, with the role of initial BDG being assessed by univariate and multivariat analyses. A total of 104 patients met the inclusion criteria. |
| Cohort No. | 104 |
| Age Group | None |
| P Value | p=0.005 |
| Sensitivity | 0.65 |
| Specificity | 0.7 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
